Q: What do you think about their announced NCIB? Since they are a growth by acquisition growth company, they have a tendency to issue shares and they need their available cash. Why would they start buying back shares in this case? Are they just trying to ‘stick it’ to the short sellers? Seems like a weird capital allocation strategy to me.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Re my Q on Ap 30,allow me to clarify that a group of Bank increased the credit of CRH by $100m to $300m after Well had completed acquisation.How come? Txs for u usual great services & views. Article by P Hodson in Financial Post on May 1 re short sellers is very educational, It appears to me that it is an opportunity to buy Well.
Q: your opinion please on recent results
Q: I am considering investing in this company. Can you please comment on the recently announced earnings. Do you like this company or is there another company in this space that you prefer. What type of return would you expect going forward? Thank You.
Q: I have a large position in Tdoc relative to my portfolio which I’ve been holding at a loss since Feb. Can I get your comments please on the earnings? I’m wondering whether to hold and hope for a recovery. My average cost is $213. Thanks.
Q: What do you think of Amgen as a long term income stock to hold through retirement? Thanks
Q: please give an opinion on the recent U.S. Patent for Treatment of Bladder Pain Syndrome and REBORN1 their 10-week open-label randomized study to evaluate the effect of inhaled QIXLEEF compared to morphine sulfate ... also, is this a buy... much thx
Q: Protalix, Is down 40%. I see no news anything at your end.
Thanks
Thanks
Q: ABBV is mentioned and recommended frequently in the 5I questions. I have heard that Humira is its strongest asset; is that the case? A BNN guest the other day referred to Humira coming off patent in 2023; does this affect its long term prospects? The company has a very healthy dividend, especially for a US entity; is this sustainable in the long term? Any other comments about ABBV? Thank you for your excellent service.
-
Intuitive Surgical Inc. (ISRG)
-
AbbVie Inc. (ABBV)
-
BMO Equal Weight REITs Index ETF (ZRE)
-
Vanguard Real Estate Index Fund ETF (VNQ)
-
Health Care Select Sector SPDR (XLV)
-
iShares U.S. Medical Devices ETF (IHI)
-
SPDR Biotech ETF (XBI)
-
Guardant Health Inc. (GH)
-
iShares U.S. Real Estate ETF (IYR)
Q: Hi group need more exposure to real estate and health care - could you recommend a few in each sector also a few ETF would be helpful. I have some ready cash to deploy but am a bit queasy about investing into todays market feels oversold? also India , South America are struggling with COVID what's you thoughts (leaning towards waiting until Virus is better controlled. Wait or jump in Appreciate your thoughts
Q: Hello,
Can I please have your updated opinion on the concerns raised in this new short report on WELL.
https://www.antya.ca/research/well-health-technologies-corp-it-is-a-bird-it-is-a-plane-noooo-it-is-a-torpedo-it-will-blow-up/
Can I please have your updated opinion on the concerns raised in this new short report on WELL.
https://www.antya.ca/research/well-health-technologies-corp-it-is-a-bird-it-is-a-plane-noooo-it-is-a-torpedo-it-will-blow-up/
Q: Good morning. Looks LLY is going to take a bit of a hit this morning. What are your thoughts on the company and it's growth potential. I have little Healthcare exposure. Would you consider this or prefer something else?
Q: My healthcare stocks include ABBV,VEEV,and Well.I am considering switching from VEEV to STRYKER. What do you think?
Q: Would you get rid of Jazz. What do you think of their unusual recent acquisition? Thanks.
Q: With Mindmeds move from OTC in the USA to the Nasdaq does this change your feelings on this new potential bio space? Once listed on Nasdaq in your opinion does this give more validation to the company? Lastly would the shares on the NEO mirror the Nasdaq listing as it starts to trade?
Q: I was interested in Jeff's follow-up comment on Excelon sales declining. Who sold it before Knight in Latam and Canada? Perhaps the reason the company made a deal with Knight is to improve visibility and awareness while giving Knight's sales force new avenues for it's other products.
The price tag does not appear to be a bargain (Knight paid $360M or double for $250M sales in Biotoscan). Surely Goodman sees value in this deal. If there was no effort before then potential must be factored in and I suspect Latam is the more coveted marketplace. Can you comment and provide any previous history with sales of this product. Alzheimers us unfortunately, not going anywhere soon.
The price tag does not appear to be a bargain (Knight paid $360M or double for $250M sales in Biotoscan). Surely Goodman sees value in this deal. If there was no effort before then potential must be factored in and I suspect Latam is the more coveted marketplace. Can you comment and provide any previous history with sales of this product. Alzheimers us unfortunately, not going anywhere soon.
-
Medical Facilities Corporation (DR)
-
NorthWest Healthcare Properties Real Estate Investment Trust (NWH.UN)
-
WELL Health Technologies Corp. (WELL)
-
Dialogue Health Technologies Inc. (CARE)
Q: Hi,
How would you rank the companies in regards to financial risk and growth?
Thank you
How would you rank the companies in regards to financial risk and growth?
Thank you
Q: Just a further comment to James' question and your answer regarding the Exelon purchase. This purchase left me scratching my head. I am a healthcare provider who works in the area where Exelon would be used. I don't see much Exelon used. As you indicated, it is a mature product. However, revenues have been declining over several years, at least according to Macrotrends (available at https://www.macrotrends.net/stocks/charts/EXC/exelon/revenue) so I don't know what rabbit GUD can pull out to wring increased revenues from this medication.
Q: Hello,
In a follow up to my prior question. Can you please give your specific take with respect to the specific issues outlined in the short report. I am aware that it may require some research so please feel free to take your time in response to this question.
- divesture of Silicon Valley buyer
- data breaches
- CRH key customer renewal not looking good
- the outbidding of itself for key assets like source 44
- circle’s shareholders cashing out.
In a follow up to my prior question. Can you please give your specific take with respect to the specific issues outlined in the short report. I am aware that it may require some research so please feel free to take your time in response to this question.
- divesture of Silicon Valley buyer
- data breaches
- CRH key customer renewal not looking good
- the outbidding of itself for key assets like source 44
- circle’s shareholders cashing out.
Q: a lot of discussions today on why WELL is so bad, yet today TD upgraded stock price from $10 to $10.50 ... is this simply showing symbolic support based on their DD, or am I reading to much into this upgrade